Terlipressin EVER Pharma

EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer

Our products include: 

AtosibanBortezomibCabazitaxelCarbetocinCerebrolysinDacepton (Apomorphine)DecitabineDexemedetomidineDocetaxelEribulinFulvestrantOxytocinPaclitaxelPemetrexedTerlipressinTestosterone EnantateTestosterone UndecanoateTrabectedin

EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany

Expertise in highly active substances and complex products

Trusted supplier to many top pharma companies and inspected by the world’s leading regulatory agencies. EVER Pharma sells products in over 70 countries worldwide, while also producing its own products.
Specialist in the manufacture of complex injectable products such as low oxygen formulations, crystal suspensions and oily solutions. This includes many highly active substances e.g., narcotics, hormones and cytotoxics.

Our state-of-the-art facility utilizes the latest innovations in production and handling. It covers a wide range of primary container formats as well as modern packaging and automated warehousing.

EVER Pharma has announced the approval of Testosterone Undecanoate in the European Union for the treatment of male hypogonadism. 

Our end-to-end services cover every aspect of pharmaceutical development, from API selection to final process validation and quality assurance, delivered with the highest level of expertise.

With state-of-the-art laboratories in Unterach (Austria) and Jena (Germany), EVER ensures that projects are developed under optimal conditions with access to specialized equipment and expertise at each critical phase.


Our team is specialized in guiding clients through the complex process to ensure safety and efficiency at every stage of development.

EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 45.

2.5mg/1ml + 3.5mg/1.4ml

EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

0.25mg + 1mg

EVER Pharma is pleased to announce EU-wide approval of Bortezomib for the treatment of patients with multiple myeloma and mantle cell lymphoma

PFS - 250mg/5ml

6.75mg/0.9ml + 37.5/5ml + 75mg/10ml

Our products include: 

AtosibanBortezomibCabazitaxelCarbetocinCerebrolysinDacepton (Apomorphine)DecitabineDexemedetomidineDocetaxelEribulinFulvestrantOxytocinPaclitaxelPemetrexedTerlipressinTestosterone EnantateTestosterone UndecanoateTrabectedin